Bruker Corporation?s announcements signal a robust commitment to advancing the scientific landscape through innovative technologies in spatial proteomics and strategic investments in drug discovery. The introduction of EpicIF? technology reaffirms Bruker?s position as a leader in the field, while the partnership with NovAliX promises to enhance the drug discovery process at a critical juncture. With the recent legal resolutions enabling a return to full operational capabilities in Germany, Bruker is poised for continued growth and innovation in the life sciences sector.